EPS for Eiger BioPharmaceuticals, Inc. (EIGR) Expected At $-0.82

July 14, 2018 - By Elizabeth Jones

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Logo

Analysts expect Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report $-0.82 EPS on August, 13.They anticipate $0.51 EPS change or 38.35 % from last quarter’s $-1.33 EPS. After having $-0.84 EPS previously, Eiger BioPharmaceuticals, Inc.’s analysts see -2.38 % EPS growth. The stock decreased 0.86% or $0.1 during the last trading session, reaching $11.5. About 64,795 shares traded. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has risen 88.41% since July 14, 2017 and is uptrending. It has outperformed by 75.84% the S&P500.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. The company has market cap of $157.97 million. The Company’s product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. It currently has negative earnings.

More news for Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) were recently published by: Seekingalpha.com, which released: “Eiger BioPharmaceuticals: Buy The Dip” on June 27, 2018. Seekingalpha.com‘s article titled: “Eiger BioPharmaceuticals A Leader In Treatment Of Viral Hepatitis?” and published on June 20, 2018 is yet another important article.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.